P2035 Laserjet HP for Cartridge Toner Compatible 05A CE505A 10pk P2035n dn P2055 Toner Cartridges


  1. Home
  2. P2035 Laserjet HP for Cartridge Toner Compatible 05A CE505A 10pk P2035n dn P2055
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
10pk CE505A 05A Compatible Toner Cartridge for HP Laserjet P2035 P2035n P2055 dn
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Color:

Black

Page Output: up to 2,500 pages @ 5% coverage Model:

ce505a 05a

Type: Toner Cartridge MPN:

ce505a 05a

Compatible Model: For Laserjet P2035 P2035n P2055 P2055dn Compatible Brand: For HP
Print Technology: Laser Brand:

Unbranded/Generic

UPC:

0755899566198



published on tue nov 09 2021

P2035 Laserjet HP for Cartridge Toner Compatible 05A CE505A 10pk P2035n dn P2055 Toner Cartridges

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

P2035 Laserjet HP for Cartridge Toner Compatible 05A CE505A 10pk P2035n dn P2055 Toner Cartridges

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS